VERICEL CORP
VCELNASDAQTrading Snapshot
- Day Range
- $40.59 – $43.50
- 52-Week Range
- $28.95 – $49.32
- Volume (shares)
- 680,183
- Avg Volume (shares)
- —
- Shares Outstanding
- 51.2M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $276M
- Last Q Revenue
- $77M
- P/E Ratio
- 89.7
- P/S Ratio
- 7.2x
- EPS (TTM)
- $0.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.3%
VERICEL CORP
VCEL
StockOtter · stockotter.spaceAbout VERICEL CORP
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report it
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel: MACI And Regenerative Knee Cartilage
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington ad
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present
Canada Pension Plan Investment Board Takes Position in Vericel Corporation $VCEL
Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,400 shares o
Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE
Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biote